Norges Bank’s Vanda Pharmaceuticals VNDA Stock Holding History

Norges Bank’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-115,000	Closed	-$543K	–	1522
2025 Q2	$543K	Hold	115,000	–	–	﹤0.01%	1618
2025 Q1	$528K	Hold	115,000	–	–	﹤0.01%	1689
2024 Q4	$551K	Hold	115,000	–	–	﹤0.01%	1789
2024 Q3	$539K	Hold	115,000	–	–	﹤0.01%	1779
2024 Q2	$650K	Hold	115,000	–	–	﹤0.01%	1858
2024 Q1	$473K	Hold	115,000	–	–	﹤0.01%	1840
2023 Q4	$485K	Hold	115,000	–	–	﹤0.01%	1901
2023 Q3	$497K	Hold	115,000	–	–	﹤0.01%	1924
2023 Q2	$758K	Sell	115,000 -44,000	-28%	-$282K	﹤0.01%	1948
2023 Q1	$1.08M	Hold	159,000	–	–	﹤0.01%	1995
2022 Q4	$1.18M	Buy	+159,000	New	+$1.55M	﹤0.01%	2039

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Norges Bank's VNDA Position: Q3 2025 in Review

Norges Bank sold out of Vanda Pharmaceuticals (VNDA) in Q3 2025, closing a stake of 115,000 shares — an estimated $543K sold.

Norges Bank first reported a position in VNDA in Q4 2022 and held it in 11 quarters. The position peaked at $1.18M in Q4 2022. 150 funds tracked by Wall St. Rank hold VNDA as of Q3 2025.

Norges Bank reported no remaining Vanda Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Norges Bank sold 115,000 Vanda Pharmaceuticals shares in Q3 2025, an estimated $543K.
Norges Bank first reported a position in Vanda Pharmaceuticals in Q4 2022 and held it in 11 quarters.
Norges Bank's Vanda Pharmaceuticals position peaked at $1.18M in Q4 2022.
150 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2025.

Based on Norges Bank's 13F filing for Q3 2025.